CoreValve for High Risk and Extreme Risk Patients; The US Pivotal Trials

7_eduardo_de-marchena
Eduardo de Marchena
2014-10-30

M.D., F.A.C.C., F.A.C.P., F.S.C.A.I.
Professor of Medicine & Surgery
Associate Dean for International Medicine
Director of Interventional Cardiology
University of Miami Miller School of Medicine

More articles by this author

Stroke

Rutger-Jan Nuis 2014-10-30MD, MSc, PhDDepartment of CardiologyThoraxcenter Rotterdam, Netherlands

Intervencionismo Coronario en Venas Centrales

Jorge Villegas2014-10-30Cardiólogo IntervencionistaProfesor: F.U.C.S.Jefe de Hemodinmia Hospital Universitario Clínica San Rafael

TAVI-Induced Conduction Abnormalities

Rutger-Jan Nuis 2014-10-30MD, MSc, PhDDepartment of CardiologyThoraxcenter Rotterdam, Netherlands

In Perspective: Impact of new TAVI Devices on TAVI Complications

Eberhard Grube2014-10-30MD, FACC, FSCAIUniversity Hospital, Dept of Medicine II, Bonn, GermanyStanford University, Palo Alto, California, USA 

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

Treatment of In-Stent Restenosis in Small Vessels with Paclitaxel-Coated Balloons

Coronary artery disease (CAD) in smaller epicardial vessels occurs in 30% to 67% of patients undergoing percutaneous coronary intervention and poses particular technical challenges....

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...